• Philip Turton, Dima El-Sharkawi, Iain Lyburn, Bhupinder Sharma, Preethika Mahalingam, Suzanne D Turner, Fiona MacNeill, Laura Johnson, Stephen Hamilton, Cathy Burton, and Nigel Mercer.
• St James's Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, UK. Electronic address: philip.turton@nhs.net.
• J Plast Reconstr Aesthet Surg. 2021 Jan 1; 74 (1): 13-29.

AbstractBreast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T cell Non-Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA-ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri-implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the peri-implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK) negative and strongly positive for CD30. BIA-ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en-bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimize the need for systemic treatments, reduce morbidity and the risk of poor outcomes. These guidelines provide an evidence-based and systematic framework for the assessment and treatment of patients with suspected or proven BIA-ALCL and are aimed at all clinicians involved in the care of people with breast implants.Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

23 keywords...

hide…